Selexipag interactions
Full monograph for SelexipagCheck it against another medicine
Medicines
171 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Gemfibrozil | Major | Metabolism | Coadministration with potent inhibitors of CYP450 2C8 may significantly increase the plasma concentrations of selexipag and its active metabolite. | 4 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Abiraterone Acetate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations of selexipag and its active metabolite. The interaction has not been… | 3 sources — open the full entry |
| Acetazolamide | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Adrenaline | Moderate | Antagonism | Concurrent administration of decongestants or vasoconstrictors may negate the vasodilatory effects of prostacyclin analogs in patients with pulmonary… | 6 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Amlodipine Besilate | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 7 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 7 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 7 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 7 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 7 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Articaine Hydrochloride + Epinephrine Bitartrate | Moderate | Antagonism | Concurrent administration of decongestants or vasoconstrictors may negate the vasodilatory effects of prostacyclin analogs in patients with pulmonary… | 6 sources — open the full entry |
| Asciminib | Moderate | Others | Coadministration with asciminib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. In vitro… | 1 sources — open the full entry |
| Atenolol | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 7 sources — open the full entry |
| Azilsartan Medoxomil | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 14 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…3 documented mechanisms | 14 sources — open the full entry |
| Bempedoic acid | Moderate | Metabolism | Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake… | 3 sources — open the full entry |
| Bempedoic acid + Ezetimibe | Moderate | Metabolism | Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake… | 3 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Moderate | Antagonism | Concurrent administration of decongestants or vasoconstrictors may negate the vasodilatory effects of prostacyclin analogs in patients with pulmonary… | 6 sources — open the full entry |
| Betaxolol Hydrochloride | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Bimatoprost + Timolol | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Bisoprolol Fumarate | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 7 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 7 sources — open the full entry |
| Brigatinib | Moderate | Excretion | Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 4 sources — open the full entry |
| Brimonidine Tartrate + Timolol Maleate | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Brinzolamide + Timolol | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Bumetanide | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Calamine + Zinc Oxide + Glycerine | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Canagliflozin Hemihydrate | Moderate | Synergy | Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators… | 15 sources — open the full entry |
| Candesartan Cilexetil | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazide | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor…2 documented mechanisms | 14 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Absorption | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 1 sources — open the full entry |
| Captopril | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with inducers of CYP450 2C8 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A3 and/or 2B7 enzymes may reduce the plasma… | 3 sources — open the full entry |
| Carboxymethylcellulose Sodium + Glycerin | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Carvedilol | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Chlorthalidone | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Clonidine Hydrochloride | Moderate | Synergy | Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor… | 7 sources — open the full entry |
| Clopidogrel + Aspirin | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 2C8 may increase exposure to the active metabolite of selexipag. Selexipag and its active metabolite are… | 5 sources — open the full entry |
| Clopidogrel Bisulphate | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 2C8 may increase exposure to the active metabolite of selexipag. Selexipag and its active metabolite are… | 5 sources — open the full entry |
| Copper Peptide + Procapil + Niacinamide + Biotin + L-Arginine | Moderate | Synergy | Coadministration of L-arginine or L-citrulline may potentiate the hypotensive effects of nitrates and vasodilators. Both L-arginine and L-citrulline are amino… | 1 sources — open the full entry |
| Dapagliflozin Propanediol | Moderate | Synergy | Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators… | 15 sources — open the full entry |
| Darolutamide | Moderate | Metabolism | Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP)… | 3 sources — open the full entry |
| Deferasirox | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 2C8 may increase exposure to the active metabolite of selexipag. Selexipag and its active metabolite are… | 5 sources — open the full entry |
| Dextromethorphan + Phenylephrine + Triprolidine | Moderate | Antagonism | Concurrent administration of decongestants or vasoconstrictors may negate the vasodilatory effects of prostacyclin analogs in patients with pulmonary… | 6 sources — open the full entry |
Food & lifestyle
food
MinorAbsorption
Food prolongs the gastrointestinal absorption of selexipag. When taken with food, the time to peak concentration (Tmax) was delayed and peak plasma concentration (Cmax) was approximately 30% lower.
What to do: Selexipag may be taken with or without food. Tolerability may be improved when taken with food.
1 source
- "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc (2016):
Conditions
Conditions in which Selexipag needs care, as documented in this source.
Kidney Diseases
ModerateNo adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2. There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.
1 source
- "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc (2016):
Liver Failure
ModerateLiver impairment can increase exposure to selexipag and its metabolites. No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment. There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.
1 source
- "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc (2016):